Pharmaceutical companies in Switzerland claim to have drugs that can help Corona patients, what is it? All pages

KOMPAS.com – A drug company in Switzerland, Roche, said the products it sells to relieve inflammation can help patients Covid-19 no need for a breathing machine.

Quoting Al Jazeera, Saturday (19/9/2020), the claim is the result of the first major research observed in Hispanic people and black people.

In that study, Roche tested tocilizumab, which is now sold under the names Actemra and RoActemra to treat arthritis or rheumatoid arthritis and several other diseases.

Although not yet reviewed by independent scientists, Roche said he would soon publish the full results of this study.

In addition, they plan to talk to the authorities for the next stage.

Drug administration is done by IV or intravenous, which is a method of giving drugs by injection or intravenous infusion.

Also read: African Herbal Medicines Can Now Be Clinically Tested for Covid-19, WHO Releases Its Protocol

The drug being tested works to compress a protein called interleukin-6, which is often found in excess in patients corona virus.

Even so, the drug has failed in previous studies, when involving patients corona virus with severe symptoms.

In this latest study, Roche claims to have done so in the United States, South Africa, Kenya, Brazil, Mexico and Peru.

About 85 percent of the 389 participants were Hispanic, black, Native American and other minorities.

These groups are disproportionately affected coronavirus pandemic.

From the results of the study, about 12 percent of the people who were given the drug ended up needing a breathing machine and some died within 28 days.

Meanwhile, in patients given a placebo, the percentage was 19 percent.

Until now, it is not clear how the study results. The reason is, other drugs that work in the same way fail in rigorous experiments on patients Covid-19.

However, some observational and less scientific studies have shown a benefit from using similar drugs.

Previously, US drug company Eli Lilly and Co reported a benefit found in a study of the anti-inflammatory drug baricitinib when combined with the antiviral drug remdesivir.

On Wednesday (16/9/2020), Eli Lilly said preliminary results from testing in the early stages showed that his experimental antibody drug was promising, namely to help clear the virus.

In addition, it is also possible to reduce the need for hospitalization in mild to moderately ill patients.

Also read: See, the following are various recent studies on Covid-19

– .